UK scientist wins NC3Rs prize
For improving the welfare of laboratory mice
Prizewinner Jane Hurst's research has shown that a new way of handling laboratory mice can improve their welfare and the quality of the science they are used for.
Laboratory mice are usually picked up by their tails, which according to Hurst's study causes high levels of anxiety and stress to the animals that can influence the outcome of experiments. By simply catching the mice using a plastic tunnel or cupped hands anxiety can be greatly reduced.
The number of mice used in the UK annually is approximately 2.6 million.
Hurst, from the University of Liverpool, received a £10,000 prize grant, which is sponsored by GlaxoSmithKline (GSK), plus a personal award of £1,000. She plans to use the prize to provide training for scientists and animal care staff on handling methods and also to assess the effects of different handling methods on stress physiology.
‘I hope our research will be universally implemented across laboratories to improve animal welfare for all mice and to minimise the effects of handling on experiments. This is a small change that is easily applied and will make a big difference to animal welfare,’ she said.
The NC3Rs prize recognises and rewards excellence in research that helps to reduce the number and suffering of animals used for scientific purposes.
The Wellcome Trust and NC3Rs also funded the research.
The research was published in Nature Methods magazine.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance
GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors
GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence